Research analysts at Northland Securities assumed coverage on shares of Esperion Therapeutics Inc (NASDAQ:ESPR) in a report issued on Tuesday. The brokerage set an “outperform” rating and a $72.00 price target on the biopharmaceutical company’s stock. Northland Securities’ price objective would indicate a potential upside of 49.75% from the company’s current price.

Several other brokerages also recently commented on ESPR. Jefferies Group LLC initiated coverage on Esperion Therapeutics in a report on Monday, July 10th. They issued a “hold” rating and a $55.00 target price on the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $60.00 price objective (up previously from $45.00) on shares of Esperion Therapeutics in a report on Monday, June 26th. UBS AG reaffirmed a “buy” rating and set a $57.00 price objective (up previously from $52.00) on shares of Esperion Therapeutics in a report on Tuesday, June 27th. Citigroup Inc. reaffirmed a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, June 22nd. Finally, Zacks Investment Research raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $48.89.

Esperion Therapeutics (NASDAQ ESPR) opened at 48.08 on Tuesday. The stock has a 50 day moving average price of $47.12 and a 200-day moving average price of $37.64. Esperion Therapeutics has a 12-month low of $9.40 and a 12-month high of $57.38. The firm’s market cap is $1.09 billion.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing the consensus estimate of ($1.67) by $0.25. During the same period last year, the business earned ($0.62) earnings per share. Equities analysts forecast that Esperion Therapeutics will post ($7.33) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Esperion Therapeutics Inc (ESPR) Coverage Initiated at Northland Securities” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/31/esperion-therapeutics-inc-espr-coverage-initiated-at-northland-securities.html.

Hedge funds have recently modified their holdings of the stock. Quantbot Technologies LP acquired a new stake in shares of Esperion Therapeutics during the first quarter valued at approximately $158,000. C WorldWide Group Holding A S acquired a new stake in shares of Esperion Therapeutics during the first quarter valued at approximately $162,000. Princeton Alpha Management LP acquired a new stake in shares of Esperion Therapeutics during the first quarter valued at approximately $205,000. Tower Research Capital LLC TRC boosted its stake in shares of Esperion Therapeutics by 69,371.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 4,856 shares during the last quarter. Finally, Bank of Montreal Can boosted its stake in shares of Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 6,000 shares during the last quarter. Institutional investors own 83.33% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Stock Ratings for Esperion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc and related stocks with our FREE daily email newsletter.